Literature DB >> 15005930

Primary total hip replacement: a comparison of a nationally agreed guide to best practice and current surgical technique as determined by the North West Regional Arthroplasty Register.

M H A Malik1, A K Gambhir, L Bale, N Pradhan, M L Porter.   

Abstract

BACKGROUND: In 1999, a statement of best practice in primary total hip replacement was approved by the Council of the British Orthopaedic Association (BOA) and by the British Hip Society (BHS) to provide a basis for regional and national auditable standards. We have compared practice in the North West Region of England to this document to ascertain adherence to this guide to best practice.
METHODS: A total of 86 surgeons from 26 hospitals were included in a questionnaire study.
RESULTS: A mean of 93.3% of operations were performed in the surgeon's usual theatre. All of these theatres had vertical laminar air flow systems. Of respondents, 42.2% routinely used exhaust suits, 68.1% routinely used impermeable disposable gowns, and 26.1% used impermeable re-usable gowns. The Charnley femoral and acetabular prostheses were the most commonly used prostheses. All surgeons used some form of anti-thromboembolic prophylaxis: 66.2% use a combination of both mechanical and chemical means. All surgeons used antibiotic prophylaxis. The most popular choice of antibiotic was a cephalosporin--70.7% used a 3-dose regimen over 24 h, 2.6% of surgeons continued antibiotic prophylaxis for 48 h after surgery, and 93.7% of surgeons routinely use antibiotic-loaded cement. All surgeons routinely cleaned, irrigated and dried the acetabulum and femur before cement insertion. Only one surgeon did not use any form of femoral canal occlusion. 69.4% used an intramedullary bone block. Retrograde filling of the femoral shaft by means of a cement gun was practised by 65.1%.
CONCLUSIONS: This study has demonstrated considerable variation of practice in total hip arthroplasty across the North West Region and significant divergence from the statement of best practice approved by the BOA and BHS. The introduction of a properly funded national hip register will surely help to clarify the effect of such diverse practice on patient outcome. We would recommend that all trusts locally audit their practices and correlate them with these nationally agreed guidelines.

Entities:  

Mesh:

Year:  2004        PMID: 15005930      PMCID: PMC1964161          DOI: 10.1308/003588404322827509

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  5 in total

1.  Comfort assessment of personal protection systems during total joint arthroplasty using a novel multi-dimensional evaluation tool.

Authors:  M H A Malik; Elizabeth Handford; Elaine Staniford; A K Gambhir; P R Kay
Journal:  Ann R Coll Surg Engl       Date:  2006-09       Impact factor: 1.891

2.  Survivorship of 2000 tapered titanium porous plasma-sprayed femoral components.

Authors:  Adolph V Lombardi; Keith R Berend; Thomas H Mallory; Michael D Skeels; Joanne B Adams
Journal:  Clin Orthop Relat Res       Date:  2008-10-31       Impact factor: 4.176

Review 3.  Does the type of surgical drape (disposable versus non-disposable) affect the risk of subsequent surgical site infection?

Authors:  David C Kieser; Michael C Wyatt; Andrew Beswick; Setor Kunutsor; Gary J Hooper
Journal:  J Orthop       Date:  2018-05-07

4.  Genetic susceptibility to total hip arthroplasty failure: a case-control study on the influence of MMP 1 gene polymorphism.

Authors:  Yiguo Yan; Jianzhong Hu; Hongbin Lu; Wenjun Wang
Journal:  Diagn Pathol       Date:  2014-09-26       Impact factor: 2.644

5.  The role of antibiotic-loaded bone cement in complicated knee arthroplasty: relevance of gentamicin allergy and benefit from revision surgery - a case control follow-up study and algorithmic approach.

Authors:  Benjamin Thomas; Maria Benedikt; Ali Alamri; Florian Kapp; Rainer Bader; Burkhard Summer; Peter Thomas; Eva Oppel
Journal:  J Orthop Surg Res       Date:  2020-08-12       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.